Bone-marrow transplantation for haematological malignancy in childhood.
Twenty-three children with haematological malignancies and a poor prognosis underwent bone-marrow transplantation. Thirteen children had acute lymphoblastic leukaemia, eight had acute nonlymphoblastic leukaemia, one had chronic myeloid leukaemia and one had malignant histiocytosis. One child was in relapse at the time of transplant and 22 were in first or subsequent remission. Before transplantation all patients received cyclophosphamide (60 mg/kg) on two consecutive days followed by total body irradiation given as a single dose of 10 Gy at 0.18 Gy/min (one patient) or 0.07 Gy/min (three patients), or as a fractionated dose of 10-12 Gy at 0.07-0.1 Gy/min (19 patients). One child with malignant histiocytosis also received two doses of etoposide (5 mg/kg). Methotrexate was given after transplantation to prevent or modify graft-versus-host disease (GVHD). One patient who received a transplant in relapse died early from overwhelming bacterial sepsis. Twenty-two patients engrafted, and of these 11 developed acute GVHD; five developed chronic GVHD; seven developed interstitial pneumonitis, with four deaths; and five relapsed between three and 12 months after transplantation, with three deaths. Fifty-nine per cent (13/22) of patients who received a transplant during remission remain in continuous complete remission and 68% (15/22) have survived for a median of 18 months (range, four to 73 months). Bone-marrow transplantation that is undertaken during remission of disease offers a prolonged disease-free survival in selected childhood malignancies.
D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000209:etiology; D005069:Evaluation Studies as Topic; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D007278:Injections, Spinal; D007938:Leukemia / Q000628:therapy*; D007945:Leukemia, Lymphoid / Q000628:therapy; D008206:Lymphatic Diseases / Q000628:therapy; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D011014:Pneumonia / Q000209:etiology; D011292:Premedication; D011379:Prognosis; D012008:Recurrence; D013997:Time Factors; D014184:Transplantation, Homologous / Q000009:adverse effects; D014916:Whole-Body Irradiation / Q000379:methods
D003520:Cyclophosphamide; D008727:Methotrexate